iOCT for Patients With Diabetic Macular Edema
Primary Purpose
Diabetic Macular Edema
Status
Recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
intraoperative OCT
stand-alone OCT
Sponsored by
About this trial
This is an interventional diagnostic trial for Diabetic Macular Edema
Eligibility Criteria
Inclusion Criteria:
- Cataract with the indication for surgery (visual symptoms) for both groups (study and control group)
- Diabetic macula edema - for the study group
- Age 21 and older
- written informed consent prior to surgery
Exclusion Criteria:
- Any relevant corneal disease
- In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age)
Sites / Locations
- Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital ViennaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
study group
controll group
Arm Description
only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
Outcomes
Primary Outcome Measures
macular thickness
macular thickness is measured with the central subfield thickness function
Secondary Outcome Measures
Full Information
NCT ID
NCT03328715
First Posted
October 29, 2017
Last Updated
September 15, 2022
Sponsor
Vienna Institute for Research in Ocular Surgery
1. Study Identification
Unique Protocol Identification Number
NCT03328715
Brief Title
iOCT for Patients With Diabetic Macular Edema
Official Title
iOCT in Patients With Diabetic Macular Edema Scheduled for Phakoemulsification - a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2016 (Actual)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vienna Institute for Research in Ocular Surgery
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Patients will be examined before and after surgery with a stand-alone OCT and intraoperative microscope integrated OCT
Detailed Description
48 patients with and 48 patients without diabetic macular edema will be recruited for the study. Macular thickness measured with a stand-alone OCT and an intraoperative OCT will be assessed before and after phakoemulsification with intraocular lens Implantation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
study group
Arm Type
Active Comparator
Arm Description
only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
Arm Title
controll group
Arm Type
Sham Comparator
Arm Description
only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
Intervention Type
Device
Intervention Name(s)
intraoperative OCT
Intervention Description
before and after surgery intraoperative OCT is performed
Intervention Type
Device
Intervention Name(s)
stand-alone OCT
Intervention Description
before and after surgery stand-alone OCT is performed
Primary Outcome Measure Information:
Title
macular thickness
Description
macular thickness is measured with the central subfield thickness function
Time Frame
2 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Cataract with the indication for surgery (visual symptoms) for both groups (study and control group)
Diabetic macula edema - for the study group
Age 21 and older
written informed consent prior to surgery
Exclusion Criteria:
Any relevant corneal disease
In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Oliver Findl, MD, Prof
Email
oliver.findl@wgkk.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oliver Findl, MD, Prof
Organizational Affiliation
Vienna Institute for Research in Ocular Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver Findl, MD, MBA
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
iOCT for Patients With Diabetic Macular Edema
We'll reach out to this number within 24 hrs